NASDAQ: XRTXXortx Therapeutics Inc Stock
$2.94-0.06 (-2%)
Updated Apr 23, 2024
XRTX Price
$2.94
Fair Value Price
$0.58
Market Cap
$5.88M
52 Week Low
$1.98
52 Week High
$7.52
P/E
-0.95x
P/B
1.33x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.76M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$8M
Beta
-0.02
Next Earnings
May 15, 2024
Ex-Dividend
N/A
Next Dividend
N/A
XRTX Overview
XORTX Therapeutics Incorporated, a bio-pharmaceutical company, develops and commercializes therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It developed XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease, XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection by suppressing acute kidney injury and associated health consequences, and XRx-221, a xanthine oxidase inhibitor candidate for the treatment of diabetic nephropathy. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XRTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XRTX ($2.94) is overvalued by 410.9% relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XRTX ($2.94) is not significantly undervalued (410.9%) relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XRTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XRTX due diligence checks available for Premium users.
Be the first to know about important XRTX news, forecast changes, insider trades & much more!
XRTX News
Valuation
XRTX fair value
Fair Value of XRTX stock based on Discounted Cash Flow (DCF)
Price
$2.94
Fair Value
$0.58
Overvalued by
410.90%
XRTX ($2.94) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XRTX ($2.94) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XRTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XRTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.95x
Industry
16.46x
Market
41.92x
XRTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.33x
Industry
5.93x
XRTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XRTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$987.7k
Profit Margin
0%
XRTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.9M
Liabilities
$410.2k
Debt to equity
0.09
XRTX's short-term assets ($3.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XRTX's short-term assets ($3.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XRTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$793.1k
Investing
-$5.4k
Financing
-$12.4k
XRTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XRTX vs Biotech Stocks
Xortx Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.